Mannatech Reports $15.2M Loss as Sales Decline and Cash Dwindles

FLOWER MOUND, TX – April 17, 2026 – Global health and wellness company Mannatech, Incorporated (NASDAQ: MTEX) capped a difficult fiscal year, reporting a significant net loss of $15.2 million for 2025. The results mark a dramatic reversal from the $2.5 million net income posted in 2024 and reflect a company grappling with declining sales, operational stumbles, and increasing financial pressure.

Full-year net sales for 2025 fell 8.3% to $108.0 million, down from $117.9 million in the prior year. The fourth quarter showed a similar trend, with net sales decreasing 8.2% to $26.6 million compared to the same period in 2024. While the company attributed a large portion of the staggering annual loss to non-cash tax adjustments, the underlying performance reveals significant operational headwinds and questions about its trajectory in a competitive market.

A Year of Setbacks: Deconstructing the Financials

The headline figure of an $8.00 per-share loss, compared to a $1.32 per-share income in 2024, was driven primarily by a massive $12.3 million income tax provision. According to the company's report, this included an $11.5 million non-cash deferred income tax expense. This accounting charge stems from management's reassessment of the value of its deferred tax assets and liabilities related to undistributed earnings in foreign subsidiaries.

These adjustments caused a dramatic swing on the balance sheet, flipping a net deferred tax asset of $1.8 million at the end of 2024 into a net deferred tax liability of $9.7 million by the end of 2025. While management stressed that this does not represent a current cash tax obligation, such a significant re-evaluation often points to changing expectations about future profitability across different jurisdictions.

Beyond the tax-related figures, the company’s core operations also showed signs of strain. Gross profit margins shrank from 77.6% in 2024 to 74.9% in 2025, which the company attributed to supply chain challenges, including higher product and freight costs. The firm recorded an operating loss of $0.4 million for the year, a decline from the $1.4 million operating income it generated in 2024.

Operational Hurdles and Regional Headwinds

Digging into the sales decline reveals a combination of internal missteps and external pressures. In a statement, President and CEO Landen Fredrick acknowledged the difficulties, pointing to specific challenges in the company's key markets.

“2025 was a challenging year for Mannatech, particularly in North America, where system-related issues affected our sales momentum," Fredrick stated. The press release specified that the implementation of a new ordering system was a primary culprit, responsible for approximately 15% of the total revenue decrease in the Americas. This operational fumble directly hampered the ability of its network of associates to sell products effectively in a critical market.

Meanwhile, the Asia/Pacific region, which constitutes the majority of Mannatech's business at 61.5% of total sales, continued to face “persistent economic challenges.” While sales in the region only saw a modest dip from $69.0 million to $66.4 million, the lack of growth in its largest market puts further pressure on the company to resolve issues elsewhere. These struggles highlight the vulnerability of the direct-selling model to both internal operational stability and broader macroeconomic conditions.

Cash Concerns and Cost-Cutting Measures

The operational struggles are mirrored in the company's cash flow and liquidity position, which has weakened considerably. Mannatech’s cash and cash equivalents plummeted from $11.4 million at the end of 2024 to just $6.2 million as of December 31, 2025. The company reported a net cash outflow from operating activities of $2.8 million for the year.

This tightening liquidity has reportedly drawn scrutiny. Recent, though delayed, regulatory filings indicate that the company’s independent auditor had discussions with management about the possibility of a “going concern” issue—a formal accounting term questioning a company's ability to meet its financial obligations for the next year. This raises the stakes for Mannatech's turnaround efforts.

In response to the financial pressure, management has emphasized its focus on running a “lean organization.” The company successfully reduced total operating expenses by $8.6 million in 2025 through cuts in payroll-related costs, warehouse expenses, and other administrative overhead. “We remain focused on implementing new revenue programs and incentives, operating as a lean organization, and carefully managing our expenses moving forward,” Fredrick noted in his statement. This operational discipline resulted in a near-breakeven operating result, underscoring the effectiveness of its cost-management efforts relative to the revenue decline.

A Competitive Landscape: Industry Context and Rival Performance

Mannatech’s difficulties are occurring as the broader direct-selling and wellness industries show signs of stabilization and growth. While the sector faces headwinds from economic uncertainty, several of Mannatech’s publicly traded competitors have navigated the environment with greater success, suggesting its problems are not solely industry-wide.

For instance, competitor Herbalife Ltd. reported a 6.3% year-over-year increase in net sales for its final quarter of 2025 and saw its full-year sales grow. Likewise, Nu Skin Enterprises reported results within its guidance and achieved over 50% growth in earnings for 2025. The outperformance of rivals who are also investing in technology and field support indicates that growth is possible, placing Mannatech’s company-specific issues, like its flawed ordering system rollout, in a harsher light.

The global health and wellness market remains a massive and growing opportunity, projected to expand significantly in the coming decade. Key trends include a consumer shift toward preventative care, personalized nutrition, and products that can demonstrate biological proof of their efficacy. To survive and thrive, Mannatech must not only fix its internal operational faults but also prove its strategies and product incentives can effectively compete for both customers and sales associates in this dynamic and demanding market.